Halozyme Therapeutics 2023 Q4 Financial Results and FY Earnings

Halozyme Therapeutics reported Q4 and FY 2023 financial results, highlighting its industry-leading ENHANZE® drug delivery platform with 7 approved partnered products in 100+ countries and approximately 800,000 patients treated. The company provides guidance for 2024 and a longer-term outlook through 2028, emphasizing platform expansion and development of a high-volume auto-injector.